Key facts
- Cellens’s last known valuation is $19.4M (Aug 2025).
- It has raised $7.5M across 3 recorded rounds; the latest was Early Stage VC ($6.4M) in Aug 2025.
- Notable investors include Creative Destruction Lab, SOSV, Springboard Enterprises, IndieBio, VentureWell — 19 tracked in total.
- Cellens has filed 2 Form Ds with the SEC since 2022, most recently Nov 2025 ($6.4M sold to 33 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 19 names
- ·Watchlist + deal alerts for Cellens
Funding rounds
3 roundsAbout Cellens
Developer of a cell surface scanning platform designed to assist oncologists in performing noninvasive detection of bladder cancer. The company's platform leverages the power of atomic force microscopy imaging and machine learning modeling to perform tests that quantify physio-biomarkers on cell surfaces extracted from urine samples to provide a diagnostic score for bladder cancer, enabling oncologists, urologists, and healthcare providers to reduce invasive, costly, and inaccurate procedures of bladder cancer diagnostics to optimize patient survival experience.
- Industry
- Decision/Risk Analysis
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2019
- Employees
- 10
- Website
- cellensinc.com/
- Ownership
- Privately Held (backing)
Cellens doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cellens shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cellens in its N-PORT filings yet. We sweep new filings monthly.